Authors

Ron Lanton III, ESQ

Jeff Baldetti, MBA

Jeff Baldetti, MBA, is director of biosimilars for Cardinal Health.

Gilbert T. Smolenski, JD

Gilbert T. Smolenski is an associate at McDermott, Will, & Emery LLP. He focuses his practice on intellectual property matters and works with clients in a broad range of technology sectors and represents clients in all aspects of patent litigation. While in law school, Gilbert served as a judicial extern for the Hon. Mark Davis, then of the North Carolina Court of Appeals. Gilbert was also a notes and comments editor for the Wake Forest Law Review and president of the Wake Forest Intellectual Property Student Association.

Scott Shields, MBA

Scott Shields, MBA, is an associate director of Reimbursement Policy Insights at Xcenda. In this role, Shields determines how health policy developments impact access to clients’ medical technologies, including small-molecule drugs, biologics, and devices.

April E. Weisbruch, JD

April E. Weisbruch is a partner at McDermott, Will, & Emery LLP. She focuses her practice on intellectual property (IP) matters, particularly in managing large-scale IP litigation and counseling. She works with clients in wide-ranging technology sectors, including pharmaceuticals, software applications, medical devices, organic chemistry and ballistics. April represents clients in all phases of patent litigation, from the filing of a complaint through appeal, as well as in the highly specialized post-grant proceedings before the United States Patent Trial and Appeal Board (PTAB). She has extensive deposition, hearing and trial experience in US district courts throughout the country, as well as in the US Court of Federal Claims, the US Court of Appeals for the Federal Circuit, and the PTAB. Her litigation experience includes traditional "competitor" litigation, litigation against nonpracticing entities, ANDA litigation under the Hatch-Waxman Act and §1498 litigation against the United States of America.

Amanda O'Hora

Amanda O’Hora is a senior director of Reimbursement Policy Insights at Xcenda. In this role, she has developed strategic reimbursement assessments, conducted analyses, and designed strategies to facilitate access to health care technologies. She has experience with novel oral and specialty pharmaceuticals, device and diagnostic products, and products in the biosimilars space.

Aaron Z. Savit, PhD

Aaron Z. Savit, PhD, is an intellectal property attorney with Axinn whose practice focuses on patent litigation and counseling, with an emphasis on the life sciences and biotechnology. His experience includes matters before the federal courts and the United States International Trade Commission. Aaron uses his scientific background to assist clients with biosimilars proceedings and litigation under the Hatch-Waxman Act.

Alejandro Menchaca, JD

Alejandro Menchaca is a shareholder at McAndrews, Held and Malloy, a full-service intellectual property law firm. He is also a long-standing adjunct professor in the area of intellectual property law at University of Illinois Chicago School of Law. He can be reached at